Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Salvage chemotherapy for recurrent germ cell cancer
C. R. Nichols
,
B. J. Roth
, P. J. Loehrer
, S. D. Williams
, L. H. Einhorn
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
40
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Salvage chemotherapy for recurrent germ cell cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Salvage Chemotherapy
100%
Germ Cell Tumor
100%
Clinical Trials
66%
Illness
66%
High-dose Chemotherapy
66%
Chemotherapy
33%
Bone Marrow
33%
Poor Prognosis
33%
Clinical High Risk
33%
Early Treatment
33%
Treatment Duration
33%
Salvage Therapy
33%
Patient Selection
33%
Recurrent Disease
33%
Ifosfamide
33%
Less Toxic
33%
Combination Therapy
33%
Etoposide
33%
Cisplatin
33%
Hopefulness
33%
Number of Drugs
33%
Vinblastine
33%
Peripheral Blood Stem Cells
33%
Multiple Recurrence
33%
Primary Chemotherapy
33%
Chemotherapy Dose
33%
Conventional Dose
33%
Stem Cell Support
33%
Nursing and Health Professions
Germ Cell Cancer
100%
Recurrent Disease
66%
Drug Megadose
66%
Diseases
66%
Combination Therapy
33%
Treatment Duration
33%
Angiographic Catheter
33%
Cisplatin
33%
Vinblastine
33%
Etoposide
33%
Ifosfamide
33%
Salvage Therapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Germ Cell Cancer
100%
Clinical Trial
50%
Recurrent Disease
50%
High Dose Chemotherapy
50%
Diseases
50%
Combination Therapy
25%
Cisplatin
25%
Ifosfamide
25%
Etoposide
25%
Vinblastine
25%